GSK Files for EU Expansion of RSV Vaccine to Younger Adults

GSK Seeks EU Approval to Broaden RSV Vaccine Use to Adults 18+

Pharmaceutical giant GSK has submitted a regulatory application to the European Medicines Agency (EMA) seeking approval to expand the use of its respiratory syncytial virus (RSV) vaccine to include adults aged 18 and older. This move marks a significant step in GSK’s efforts to widen access to its RSV vaccine, which is currently approved for use in older adults.

Broader Protection Against RSV

RSV is a common respiratory virus that can cause serious illness, particularly in infants, the elderly, and individuals with compromised immune systems. While severe cases are typically associated with infants and older adults, recent studies have shown that younger adults, especially those with underlying medical conditions, may also be at increased risk of complications from RSV infections.

Currently, GSK’s RSV vaccine, marketed under the brand name Arexvy, is approved in several regions, including the European Union and the United States, for use in adults aged 60 and above. The new application aims to expand this authorization to include adults starting at 18 years old, potentially protecting a broader segment of the population.

Clinical Trial Data Supports Expanded Use

The EMA submission is backed by data from recent clinical trials that demonstrated the vaccine’s safety and efficacy in younger adult populations. The studies indicated that the vaccine effectively reduces the risk of lower respiratory tract disease caused by RSV in adults aged 18 to 59, with a favorable safety profile comparable to that observed in older adults.

Dr. Phil Dormitzer, GSK’s Senior Vice President and Head of Vaccines R&D, emphasized the importance of the expanded indication. "RSV is not only a threat to infants and seniors. Our data shows that many adults with underlying health conditions can also suffer serious illness from RSV. Expanding vaccine access could help prevent hospitalizations and improve outcomes for these at-risk groups," he stated.

EU Review Process Underway

The EMA will now review GSK’s application under its centralized authorization procedure. If approved, the expanded label would allow healthcare providers across EU member states to offer the vaccine to a much wider adult population, potentially helping to reduce the overall burden of RSV infections across Europe.

Growing Global Competition in RSV Market

GSK is one of several major pharmaceutical companies investing heavily in RSV vaccine development. Competitors such as Pfizer and Moderna are also advancing their own RSV vaccines, targeting various age groups and risk categories. The race to capture market share in the RSV vaccine segment has intensified as global health agencies prioritize expanded vaccination strategies to address respiratory illnesses.

Outlook Positive as RSV Vaccine Market Expands

Analysts expect GSK’s latest regulatory filing to strengthen its position in the rapidly growing RSV vaccine market. If approved, the expanded indication could significantly increase the company’s revenue potential while providing important public health benefits by reducing RSV-related complications across a broader demographic.